CN104189579A - Traditional Chinese medicine composition for treating jaundice due to liver cancer - Google Patents
Traditional Chinese medicine composition for treating jaundice due to liver cancer Download PDFInfo
- Publication number
- CN104189579A CN104189579A CN201410432099.2A CN201410432099A CN104189579A CN 104189579 A CN104189579 A CN 104189579A CN 201410432099 A CN201410432099 A CN 201410432099A CN 104189579 A CN104189579 A CN 104189579A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- parts
- medicine composition
- jaundice
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010023126 Jaundice Diseases 0.000 title claims abstract description 46
- 239000003814 drug Substances 0.000 title claims abstract description 32
- 239000000203 mixture Substances 0.000 title claims abstract description 27
- 201000007270 liver cancer Diseases 0.000 title abstract description 6
- 208000014018 liver neoplasm Diseases 0.000 title abstract description 6
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims abstract description 5
- 238000002560 therapeutic procedure Methods 0.000 claims description 19
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 18
- 239000004480 active ingredient Substances 0.000 claims description 7
- 239000002994 raw material Substances 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 241000628997 Flos Species 0.000 claims description 4
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 238000005469 granulation Methods 0.000 claims description 2
- 230000003179 granulation Effects 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 3
- 239000002552 dosage form Substances 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 6
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 244000025254 Cannabis sativa Species 0.000 abstract 1
- 241001547127 Fritillaria cirrhosa Species 0.000 abstract 1
- 241001598107 Imperata Species 0.000 abstract 1
- 244000167230 Lonicera japonica Species 0.000 abstract 1
- 235000017617 Lonicera japonica Nutrition 0.000 abstract 1
- 244000197580 Poria cocos Species 0.000 abstract 1
- 235000008599 Poria cocos Nutrition 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 20
- 239000008280 blood Substances 0.000 description 20
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical group N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 14
- 208000002193 Pain Diseases 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 9
- 206010011224 Cough Diseases 0.000 description 7
- 210000000013 bile duct Anatomy 0.000 description 7
- 206010023129 Jaundice cholestatic Diseases 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 201000005267 Obstructive Jaundice Diseases 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 206010030113 Oedema Diseases 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 208000001780 epistaxis Diseases 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 201000000736 Amenorrhea Diseases 0.000 description 3
- 206010001928 Amenorrhoea Diseases 0.000 description 3
- 208000015220 Febrile disease Diseases 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 231100000540 amenorrhea Toxicity 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 238000002651 drug therapy Methods 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 206010043458 Thirst Diseases 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 210000003445 biliary tract Anatomy 0.000 description 2
- BPYKTIZUTYGOLE-UHFFFAOYSA-N billirubin-IXalpha Natural products N1C(=O)C(C)=C(C=C)C1=CC1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(C=C3C(=C(C=C)C(=O)N3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-UHFFFAOYSA-N 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 208000017574 dry cough Diseases 0.000 description 2
- 206010013990 dysuria Diseases 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- HVHKMUMXERBUAN-IFADSCNNSA-N mesobilirubin IXalpha Chemical compound N1C(=O)C(CC)=C(C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C)C(=O)N\3)CC)N2)CCC(O)=O)N1 HVHKMUMXERBUAN-IFADSCNNSA-N 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 231100000167 toxic agent Toxicity 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 208000031361 Hiccup Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 235000018259 Solanum vestissimum Nutrition 0.000 description 1
- 240000002825 Solanum vestissimum Species 0.000 description 1
- 208000037114 Symptom Flare Up Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000010109 chemoembolization Effects 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002603 extrahepatic bile duct Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 208000010540 rapid respiration Diseases 0.000 description 1
- 230000001373 regressive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000003786 sclera Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a traditional Chinese medicine for treating jaundice due to liver cancer, and belongs to the technology of traditional Chinese medicine. The pharmacological component of the composition is prepared from the following components in parts by weight: 10-20 parts of radix rehmanniae recen, 5-15 parts of radix ophiopogonis, 10-20 parts of rhizoma atractylodis macrocephalae, 10-20 parts of radix paeoniae alba, 15-25 parts of poria cocos, 5-15 parts of lalang grass rhizome, 5-15 parts of lonicera japonica, 5-15 parts of fritillaria cirrhosa, 5-15 parts of herba lycopi, 10-14 parts of moutan bark and 10-14 parts of radix paeoniae rubra. The traditional Chinese medicine composition has the advantages of reasonable formula, low cost and easiness for popularization, can be used for treating diseases based on overall analysis of the illness and the condition of patients by following the traditional Chinese medical theory, and has the advantages of remarkable effect and small toxic and side effect.
Description
[technical field]
The present invention relates to Chinese medicine technical field, particularly a kind of Chinese medicine composition of Hepatoma therapy jaundice.
[technical background]
Jaundice is one of common complication of mid and late liver cancer patient, the about 29.6%-37.5% of hepatocarcinoma jaundice coincidence.A kind of clinical manifestation of the xanthochromias such as the sclera that when jaundice is bilirubin metabolism obstacle, plasma bilirubin Enrichment causes, skin, mucosa, body fluid.The erythrocyte of bilirubin ex vivo aging, its generation, metabolism and excretion and liver are in close relations, and any one link generation obstacle all can cause the rising of blood mesobilirubin concentration to cause jaundice.According to the cause of disease, jaundice can be divided into three kinds of hemolytic jaundice, hepatocellular jaundice and obstructive jaundices.The concurrent jaundice of liver cancer patient belongs to latter two, common with obstructive jaundice, and concrete mechanism is as follows:
1, in liver and hepatic hilar tumor tuberosity or portal lymph node enlargement oppress bile ducts at different levels, cause biliary drainage not smooth, conjugated bilirubin and unconjugated bilirubin backflow into blood, blood mesobilirubin concentration raises, and take conjugated bilirubin as main, causes obstructive jaundice.
2, in liver, tumor is invaded bile duct, causes bile duct not exclusively or total blockage, and can partial necrosis come off, and drops to extrahepatic bile ducts, blocks suddenly biliary tract, causes obstructive jaundice, it is reported, this machine-processed incidence rate is about 1.5%-8%.
3, Tumor thrombus in bile duct, comprises that downright bad tumor comes off, and in bile duct, grows, and in liver, primary tumo(u)r is broken into bile duct, or tumor is hemorrhage, and the blood clot that contains cancerous cell forms embolus, blocks bile duct etc., all can cause obstructive jaundice.
4, diffuse liver cancer or be associated with serious liver cirrhosis, because extensively hepatocyte is impaired, generation, metabolism and the acatharsia of bilirubin in liver, cause conjugated bilirubin and unconjugated bilirubin level in blood all to raise, cause hepatocellular jaundice, also can be associated with obstructive jaundice because of the compressing of tumor in liver to biliary system, be Combination jaundice simultaneously.
5, some anti-liver cancer treatment means also can cause jaundice, as hepatic arterial chemoembolization, percutaneous Ethanol Injection, outer radiotherapy etc.
Treatment to hepatocarcinoma jaundice, merely treats by doctor trained in Western medicine method at present, cure the symptoms, not the disease often, and to patient, increased very large misery in each therapeutic process, so western medical treatment hepatocarcinoma jaundice is not best method; The determination for the treatment of based on pathogenesis obtained through differentiation of symptoms and signs of traditional Chinese medicine composition for treating hepatocarcinoma jaundice, reinforcement and elimination in combination, treating both the principal and secondary aspects of a disease that the present invention adopts, and be used for the treatment of in hepatocarcinoma jaundice case in clinical experiment, significant therapeutic effect obtained, safe without toxic side effect.
[summary of the invention]
The object of the present invention is to provide a kind of Chinese medicine composition of the jaundice of Hepatoma therapy effectively, provided by the present invention be the Chinese medicine composition of Hepatoma therapy jaundice can removing pathogenic heat from blood and toxic substance from the body, dampness removing jaundice eliminating.Hepatoma therapy jaundice, has no side effect preferably, safe and reliable.
Technical scheme of the present invention is as follows:
A Chinese medicine composition for Hepatoma therapy jaundice, is characterized in that, the active ingredient of described pharmaceutical composition is prepared from by the raw material of following weight portion:
Further, the active ingredient of preferred described pharmaceutical composition is prepared from by the raw material of following weight portion:
Further, the active ingredient of preferred described pharmaceutical composition is prepared from by the raw material of following weight portion:
Chinese medicine details in the present invention is as follows:
The Radix Rehmanniae, clearing away heat and promoting production of body fluid, removing heat from blood, hemostasis.For consumption of YIN caused by febrile disease, crimson tongue excessive thirst, send out speckle dermexanthesis, spit blood, epistaxis, laryngopharynx swelling and pain.
Radix Ophiopogonis, for dryness of the lung dry cough, chronic consumptive disease cough, Tianjin wound is thirsty, vexed insomnia, interior-heat is quenched one's thirst, dryness of the intestine constipation, pharyngeal diphtheria, YIN nourishing and the production of body fluid promoting.
The Rhizoma Atractylodis Macrocephalae, invigorating the spleen and benefiting QI, dampness diuretic, hidroschesis, antiabortive.For insufficiency of the spleen lack of appetite, abdominal distention is had loose bowels, phlegm retention vertigo and palpitation, edema, spontaneous perspiration, frequent fetal movement.
The Radix Paeoniae Alba, cool in nature, bitter in the mouth acid, is slightly cold, and has the effects such as blood-supplementing blood-nourishing, suppressing liver-YANG, easing the affected liver to relieve pain, astringing YIN to stop sweating.Be applicable to fever due to yin deficiency, menoxenia, the breast abdomen pain over the hypochondriac region, extremity contraction anxious, dysentery stomachache, spontaneous sweating, metrorrhagia, be with inferior disease.
Poria, slightly sweet flavor is flat, enters the heart, lung, spleen channel.There is eliminating dampness and diuresis, invigorating the spleen and regulating the stomach, the effect of mind tranquilizing and the heart calming.Can control dysuria, edema distension, phlegm retention cough with dyspnea, vomiting, malignant histocytosis, has loose bowels, seminal emission, stranguria with turbid discharge, palpitation with fear, forgetful disease such as grade.
Rhizoma Imperatae, has removing heat from blood, hemostasis, heat clearing away, diuresis.Control calentura excessive thirst, spit blood, epistaxis, lung-heat dyspnea with rapid respiration, gastric heat hiccup, gonorrhea, dysuria, edema, jaundice.
Flos Lonicerae, cold in nature, sweet in the mouth, enters lung, the heart, stomach warp, has the effect of heat-clearing and toxic substances removing, antiinflammatory, tonify deficiency treatment wind.
Bulbus Fritillariae Cirrhosae, clearing heat and moistening lung, preventing phlegm from forming and stopping coughing.For lung-heat type cough, the few expectorant of dry cough, deficiency of YIN chronic cough, sputum with blood.
Herba Lycopi, blood circulation promoting and blood stasis dispelling, diuresis detumescent.For amenorrhea due to stagnation of blood, disease purplish or white patches on the skin, puerperal stasis of blood pain, edema, traumatic injury.
Cortex Moutan, heat clearing away; Promoting blood circulation to remove blood stasis.The main epidemic febrile disease pathogenic heat attacking blood system in febrile diseases, sends out speckle, tells nosebleed, and the pathogenic bacteria later stage brimful of tears, hot Fu Yin divided heating, deficiency of YIN osteopyrexia and fever, and amenorrhea due to stagnation of blood, dysmenorrhea, carbuncle sore tumefacting virus, falls and flutters the pain of injury, rheumatism pyretic arthralgia.
Radix Paeoniae Rubra, clearing away heat and cooling blood, eliminating stasis to stop pain.For maculae caused by violent heat pathogen, hematemesis and epistaxis, conjunctival congestion and swelling pain, hypochondriac pain due to stagnation of liverQI, amenorrhea dysmenorrhea, lump in the abdomen stomachache, injury from falling down, carbuncle skin infection.
The present invention adopts above technical scheme, compared with prior art, have the following advantages: the patient who suffers from hepatocarcinoma jaundice has obvious jaundice regressive effect, simultaneously also can QI invigorating soothing liver and strengthening spleen, nourshing blood and promoting blood circulation pain relieving, removing pathogenic heat from blood and toxic substance from the body, dampness removing dissipating blood stasis, improve patient's life quality, through test, effective percentage can reach 80%.
Below in conjunction with the specific embodiment, technical scheme of the present invention is described further.
[specific embodiment]
Embodiment 1
Treat a Chinese medicine composition for Hepatoma therapy jaundice, by following component, according to weight classification, form (every part of 1g);
After forming according to above weight classification, temperature fire decocts 1.5 hours-2 hours, decocts rear collecting decoction twice, filters, and makes oral liquid.
Embodiment 2
Treat a Chinese medicine composition for Hepatoma therapy jaundice, by following component, according to weight classification, form (every part of 1g);
After forming according to above weight classification, temperature fire decocts 1.5 hours-2 hours, decoct rear collecting decoction twice, filter, be concentrated into the paste that relative density is 1.30-1.35, dry below 80 degree again,, be ground into fine powder, add adjuvant (starch oar 10%, dextrin 10%, lactose 5%, dry starch 5%, stearic acid 2%, mannitol 1%, Talcum acid 2%), mix, make capsule.
Embodiment 3
Treat a Chinese medicine composition for Hepatoma therapy jaundice, by following component, according to weight classification, form (every part of 1g);
After forming according to above weight classification, temperature fire decocts 1.5 hours-2 hours, decoct rear collecting decoction twice, filter, be concentrated into the paste that relative density is 1.30-1.35, dry below 80 degree again,, be ground into fine powder, add adjuvant (starch oar 10%, dextrin 10%, lactose 5%, dry starch 5%, stearic acid 2%, magnesium stearate 1%, Talcum acid 2%), mix granulation.
Test by above three embodiment gained medicines for hepatocarcinoma jaundice, use efficacy assessment standard to be:
Effective: jaundice disappears completely, symptom alleviates or disappears; Stable: jaundice does not disappear completely, but subdues to some extent; Worsen: symptom increases the weight of, jaundice increases the weight of, even occur that patient goes into a coma, hemorrhage, shock phenomenon.
The 120 routine hepatocarcinoma Patients with Jaundices of seeking medical advice year March in February, 2010 to 2014, patient's disease meets < < Internal Medicine-Oncology and learns the diagnostic criteria of > > third edition hepatocarcinoma jaundice.120 examples are all hepatocarcinoma jaundice through proved by pathology, male 69 examples, female's 51 examples, age 40-80 year, the course of disease 1 month to 1 year.
This test is provided with 3 test group altogether, and each test group random assortment patient treats.Test group 1 use-case 1 gained Drug therapy, test group 2 is used the Drug therapy of embodiment 2 gained, test group 3 is used the Drug therapy of embodiment 3 gained, if 30 examples are matched group, matched group adopts doctor trained in Western medicine to adopt methods of hormonal treatment or artificial liver auxiliary treating method to carry out, and total effective rate is 50%.
Resulting result is as following table:
| Test group | Number of cases | Effective | Stable | Worsen | Effective percentage (%) |
| Test group 1 | 30 | 10 | 10 | 10 | 67％ |
| Test group 2 | 30 | 14 | 10 | 6 | 80％ |
| Test group 3 | 30 | 12 | 9 | 9 | 70％ |
| Matched group | 30 | 7 | 8 | 15 | 50％ |
From above data analysis, can draw the medicine of gained Hepatoma therapy jaundice of the present invention, total effective rate reaches more than 67%, safe and reliable, have no side effect, and embodiment 2 is preferred plan, and effective percentage can reach 80%.
Although for reaching illustration purpose, the above is disclosed as the preferred embodiments of the present invention, be not limited to the present invention, although the present invention is had been described in detail with reference to previous embodiment, for a person skilled in the art, its technical scheme that still can record aforementioned each embodiment be modified, or part technical characterictic is wherein equal to replacement.Within the spirit and principles in the present invention all, any modification of doing, be equal to replacement, improvement etc., within all should being included in protection scope of the present invention.
Claims (8)
1. a Chinese medicine composition for Hepatoma therapy jaundice, is characterized in that, the active ingredient of described Chinese medicine composition is prepared from by the raw material of following weight portion:
。
2. a Chinese medicine composition for Hepatoma therapy jaundice, is characterized in that, the active ingredient of described Chinese medicine composition is prepared from by the raw material of following weight portion:
。
3. the Chinese medicine composition of Hepatoma therapy jaundice as claimed in claim 1, is characterized in that, the active ingredient of described Chinese medicine composition is prepared from by the raw material of following weight portion:
。
4. the Chinese medicine composition of Hepatoma therapy jaundice as claimed in claim 1, is characterized in that, the active ingredient of described Chinese medicine composition is prepared from by the raw material of following weight portion:
5. the Chinese medicine composition of Hepatoma therapy jaundice as claimed in claim 1 or 2 or 3 or 4, is characterized in that, the dosage form of described Chinese medicine composition is oral liquid, granule, capsule or tablet.
6. the production method of the Chinese medicine composition of Hepatoma therapy jaundice as claimed in claim 1 or 2 or 3 or 4, it is characterized in that, get by weight ratio the Radix Rehmanniae, Radix Ophiopogonis, the Rhizoma Atractylodis Macrocephalae, the Radix Paeoniae Alba, Poria, Rhizoma Imperatae, Flos Lonicerae, Bulbus Fritillariae Cirrhosae, Herba Lycopi, Cortex Moutan, Radix Paeoniae Rubra, by gross weight, add doubly warm fiery decoction 1.5 hours-2 hours of water 3-5, decoct rear collecting decoction twice, filter, make oral liquid.
7. the production method of the medicine of Hepatoma therapy jaundice as claimed in claim 1 or 2 or 3 or 4, it is characterized in that, get by weight ratio the Radix Rehmanniae, Radix Ophiopogonis, the Rhizoma Atractylodis Macrocephalae, the Radix Paeoniae Alba, Poria, Rhizoma Imperatae, Flos Lonicerae, Bulbus Fritillariae Cirrhosae, Herba Lycopi, Cortex Moutan, Radix Paeoniae Rubra, by gross weight, add doubly warm fiery decoction 1.5 hours-2 hours of water 3-5, decoct rear collecting decoction twice, filter; Be concentrated into the paste that relative density is 1.30-1.35, then dry, pulverize into fine powder below 80 degree, add adjuvant, mix, make capsule.
8. the production method of the medicine of Hepatoma therapy jaundice as claimed in claim 1 or 2 or 3 or 4, it is characterized in that, get by weight ratio the Radix Rehmanniae, Radix Ophiopogonis, the Rhizoma Atractylodis Macrocephalae, the Radix Paeoniae Alba, Poria, Rhizoma Imperatae, Flos Lonicerae, Bulbus Fritillariae Cirrhosae, Herba Lycopi, Cortex Moutan, Radix Paeoniae Rubra, by gross weight, add doubly warm fiery decoction 1.5 hours-2 hours of water 3-5, decoct rear collecting decoction twice, filter; Be concentrated into the paste that relative density is 1.30-1.35, then dry, pulverize into fine powder below 80 degree, add adjuvant, mix granulation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410432099.2A CN104189579B (en) | 2014-08-28 | 2014-08-28 | A kind of Chinese medicine composition for treating liver cancer jaundice |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410432099.2A CN104189579B (en) | 2014-08-28 | 2014-08-28 | A kind of Chinese medicine composition for treating liver cancer jaundice |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104189579A true CN104189579A (en) | 2014-12-10 |
| CN104189579B CN104189579B (en) | 2017-11-21 |
Family
ID=52075050
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410432099.2A Expired - Fee Related CN104189579B (en) | 2014-08-28 | 2014-08-28 | A kind of Chinese medicine composition for treating liver cancer jaundice |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104189579B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108186951A (en) * | 2018-03-20 | 2018-06-22 | 晋云 | A kind of preparation method for the Chinese medicine composition for being used to treat hepatic carcinoma |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101961464A (en) * | 2010-04-27 | 2011-02-02 | 泰一和浦（北京）中医药研究院有限公司 | Chinese medicinal composition for treating jaundice and preparation method thereof |
| CN102764411A (en) * | 2012-07-13 | 2012-11-07 | 张清宝 | Drug composite for curing jaundice and preparation method thereof |
| CN103800456A (en) * | 2014-01-24 | 2014-05-21 | 刘璐 | Traditional Chinese medicine composition for treating liver cancer |
-
2014
- 2014-08-28 CN CN201410432099.2A patent/CN104189579B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101961464A (en) * | 2010-04-27 | 2011-02-02 | 泰一和浦（北京）中医药研究院有限公司 | Chinese medicinal composition for treating jaundice and preparation method thereof |
| CN102764411A (en) * | 2012-07-13 | 2012-11-07 | 张清宝 | Drug composite for curing jaundice and preparation method thereof |
| CN103800456A (en) * | 2014-01-24 | 2014-05-21 | 刘璐 | Traditional Chinese medicine composition for treating liver cancer |
Non-Patent Citations (4)
| Title |
|---|
| 周德生等: "《中医验方全书（珍藏本）》", 31 January 2011 * |
| 唐大晅: "《药房里买得到的祖传秘方》", 30 April 2013 * |
| 常敏毅: "《实用抗癌药方》", 31 December 1993 * |
| 张树生: "《百药效用奇观》", 31 January 1988 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108186951A (en) * | 2018-03-20 | 2018-06-22 | 晋云 | A kind of preparation method for the Chinese medicine composition for being used to treat hepatic carcinoma |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104189579B (en) | 2017-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101884770B (en) | Chinese medicinal preparation for treating urolithiasis and preparation method thereof | |
| CN103656041B (en) | A kind of Chinese medicine for the treatment of cervical cancer | |
| CN103071093B (en) | Medicine for treating gynecological diseases | |
| CN105213974A (en) | One treats lymphadenomatous Chinese medicine composition and application thereof | |
| CN105343724A (en) | Traditional Chinese medicine composition for treating gynecological diseases | |
| CN103169883B (en) | Traditional Chinese medicine for treating infantile jaundice | |
| CN102973677B (en) | Traditional Chinese medicine for treating ovarian cyst | |
| CN104383317A (en) | Chinese traditional medicine composition for treating liver cancer | |
| CN103550709A (en) | Traditional Chinese medicine for treating chronic pelvic inflammation | |
| CN104001019A (en) | Traditional Chinese medicinal composition for treating seasonal allergic rhinitis | |
| CN101618201B (en) | Medicine for curing vulvar leukoplakia | |
| CN104189579A (en) | Traditional Chinese medicine composition for treating jaundice due to liver cancer | |
| CN103610772B (en) | The Chinese medicine for the treatment of cerebral thrombosis | |
| CN105770691A (en) | Medicinal preparation for treating cervical cancer and application thereof | |
| CN104491670A (en) | Traditional Chinese medicine composition for treating chronic pelvic inflammatory disease | |
| CN104288635A (en) | Traditional Chinese medicine preparation for treating wind-cold attacking lung type cough | |
| CN104644860A (en) | Medicine composition for treating inflammatory external hemorrhoids of pregnant and lying-in women and application thereof | |
| CN104288581A (en) | Traditional Chinese medicine for treating threatened abortion | |
| CN103656063A (en) | Medicine for treating chronic prostatitis | |
| CN103623287B (en) | A kind ofly treat Chinese medicine lotion of vaginitis and cervical erosion and preparation method thereof | |
| CN102240384B (en) | Medicament for treating phlegm-stasis accumulating type epilepsy and preparation method thereof | |
| CN107213443B (en) | Traditional Chinese medicine composition for treating hydronephrosis and combined application of thunder-fire moxibustion | |
| CN104189870A (en) | Traditional Chinese medicine for treating allergic asthma | |
| CN104887933A (en) | Medicine for curing accumulated damp-heat chronic pelvic inflammation | |
| CN105055665A (en) | Anti-hepatoma traditional Chinese medicine preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20171121 |